Welcome to our dedicated page for DENTSPLY SIRONA news (Ticker: $XRAY), a resource for investors and traders seeking the latest updates and insights on DENTSPLY SIRONA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DENTSPLY SIRONA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DENTSPLY SIRONA's position in the market.
Dentsply Sirona reported a decrease in net sales of 2.6% in the first quarter of 2024, with organic sales down 1.9%. The GAAP gross margin was 53.1%, with net income of $18 million or $0.09 per share. Adjusted EBITDA margin was 16.8%, with adjusted EPS of $0.42. The company is maintaining its FY24 outlook but trending towards the low-end of both organic sales and adjusted EPS ranges. Dentsply Sirona plans to repurchase up to $150 million of its common stock in Q2 2024.
